//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
The combination of cadonilimab plus axitinib demonstrated promising efficacy and a manageable safety profile as frontline therapy for advanced non–clear cell RCC. Read more ➡️ www.onclive.com/view/cadonil... #KidneyCancer #RCC #nccRCC #GUonc #Immunotherapy #kcsm #Oncology
20h
Cadonilimab plus axitinib demonstrated an ORR of 51.6% and manageable safety in frontline advanced nccRCC.
www.onclive.com
Cadonilimab Plus Axitinib Displays Efficacy, Safety in Frontline Advanced nccRCC | OncLive
OncLive